AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04878692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Application of Onco-Neutre cream
Description: The cream Onco-Neutre will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.
Study NCT05023525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31858, tablet
Description: Starting dose in single ascending dose: 5 mg
Study NCT05023525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, tablet
Description: Matching placebo
Study NCT06208605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Network Informed Personalized Treatment
Description: Idiographic network analysis is used to determine individuals' top central eating disorder symptoms. Participants then receive modules to address these specific symptoms.
Study NCT06208605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Cognitive Behavioral Therapy for Eating Disorders
Description: Manualized CBT-E (Fairburn 2008) including regular eating, self-monitoring, and CBT modules implemented flexibly.
Study NCT04253951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)-monitored feeding trial
Description: LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
Study NCT04253951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Lung Ultrasound (LUS)-monitored feeding trial
Description: LUS-monitored (before and after) feeding trial (different consistencies might be tested in separate repeated trials according to clinical evaluation). A further LUS evaluation will be performed at a distance of 3 hours, before the next meal to check for resolution of after-meal abnormalities. All pulmonary fields will be explored according to semeiotics and previous literature.
Study NCT05539118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon α1b
Description: Recombinant human interferon α1b is a protein with potent antiviral, antiproliferative and immunomodulatory properties.
Study NCT05539118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab is a recombinant, humanized programmed death receptor (PD-1) monoclonal antibody that binds to PD- and prevents binding of PD-1 with programed death ligands 1 (PD-L1) and PD-L2. It can function to activate cytotoxic T lymphocytes and inhibit tumor growth.
Study NCT05539118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR) and c-kit.
Study NCT05576701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: In this study, laughter therapy was applied to the experimental group three times a week (on Mondays, Wednesdays, and Fridays) for a total of 12 sessions. Each session started with other patients in the HD unit while the patient was receiving HD treatment (1 hour after HD started) and lasted 30-45 minutes. The number of patients who will take part in each laughter session is based on the number of patients attending that session in the hemodialysis unit.
Study NCT05576701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The patients in the control group, on the other hand, did not undergo any intervention other than their routine treatment and care. Laughter therapy was applied for four weeks to HD patients in the control group who wanted the results of the research.
Study NCT06303531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Fumarate
Description: Ferrous Fumarate - 300 mg
Study NCT06303531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polysaccharide Iron
Description: Polysaccharide Iron - 150 mg
Study NCT06303531 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Ascorbate
Description: Ferrous Ascorbate - 100 mg
Study NCT04825340 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
Description: 0.2 ml/vial, 0.2ml/dose/per person
Study NCT04825340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nasal Spray Lyophilized Live Attenuated Influenza Vaccine
Description: 0.2 ml/vial, 0.2ml/dose/per person
Study NCT05095948 — intervention group
Intervention type: PROCEDURE
Intervention: Discussion
Description: Undergo audio recording of clinic conversations
Study NCT05095948 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study NCT04977778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fatty Acids Compounds (F.A.G.) Mouthwash
Description: Fatty Acids Compounds (F.A.G.) Mouthwash
Study NCT04977778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride (SF) Mouthwash
Description: Stannous Fluoride (SF) Mouthwash
Study NCT06399458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: For hypermobility; Beighton score and Brighton revised 1998 Criteria
Description: Beighton score and Brighton revised 1998 Criteria
Study NCT05095948 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05192213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Patients will be allocated in a 1: 1 ratio to the treatment group, receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days
Study NCT05192213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 placebos (every 6 hours and every 12 hours) + Hydrocortisone (50 mg every 6 hours) for 7 days.
Study NCT05713539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal block
Description: Small sheet of copper will be used when cooled to the designated temperature
Study NCT06220019 — intervention group
Intervention type: DRUG
Intervention: TCM
Description: We will perform subgroup analyses based on specific TCM interventions (such as Chinese patent medicines or external therapies) and the duration of TCM treatment (for example, comparing patients who receive continuous oral Chinese patent medicine for two months or more each year with those who do not). These analyses will assess the efficacy and safety of TCM.
Study NCT05656781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention and Contact (BIC) based on Word Health Organization (WHO)
Description: Intervention based on: Clinical WHO - SUICIDE PREVENTION DOCUMENT MULTISITE INTERVENTION STUDY ON SUICIDAL BEHAVIOURS - SUPRE-MISS: PROTOCOL OF SUPRE-MISS. Brief Intervention and Contact with participants using follow up questions about mood or any suicide attempts.
Study NCT06506929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task specific physical therapy
Description: Physical Therapy based specifically on tasks that the participant os having difficulty with
Study NCT04425395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold pressor task (CPT)
Description: The cold pressor test is among the most common and established methods for studying human reactions to pain and pain tolerance. Participants submerge a hand in cold water (approx. 5°C) and are asked to keep their hand submerged for as long as can (until the sensation is intolerable), up to a maximum of 5 min. The procedure is safe because the hand is removed before adverse effects can occur. The participant will be given a break of 5 min in between trials, and will interchange hands between trials. During this break hand may to be place in warm water (25-35°C) for up to 4 min to normalise hand temperature, which will be measured before and after each trial using a digital thermometer held firmly in the palm of the hand.~Each participant will complete no more than three trials (conditions) in a randomised order.
Study NCT04425395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic Recordings
Description: During the experiment, the vocalizations produced will be systematically recorded for each participant and an analysis of the acoustic structure of these vocalizations will be carried out.
Study NCT04425395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Index measurement NOL™
Description: Four sensors placed non-invasively on one finger. of the participants will be able to calculate a dozen physiological parameters converts in real time into a pain index called NOL (for Nociception Level Index).
Study NCT04425395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Video pupillometry
Description: This technique is based on the observation of the dilatation of the pupil during the perception of a nociceptive stimulus in test persons.
Study NCT05103215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine HCl 2%
Description: Intravenous injection of 1.5 mg/kg lidocaine at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
Study NCT05103215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous injection of 1.5 mg/kg normal saline at induction of anesthesia and continuous infusion of 1.5 mg/kg/h (ideal body weight) through the maintenance period to one hour after operation.
Study NCT05934175 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive treatment with prolonged exposure
Description: Intensive treatment with prolonged exposure
Study NCT05934175 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weekly delivered prolonged exposure
Description: Weekly delivered prolonged exposure sessions for 15 weeks
Study NCT05870761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05870761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo MRI/CT
Study NCT05870761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Given IV
Study NCT05870761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI/CT
Study NCT06267066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate 0.1% Cream
Description: Moderate potency
Study NCT06267066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartXide® fractional carbon dioxide laser
Description: Ablative
Study NCT06267066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline Topical Product
Description: Emollient
Study NCT05018026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutri-Grade labels
Description: All beverage products in the arm are displayed with the Nutri-Grade label. This label was proposed by the Ministry of Health in Singapore to be implemented at the end of 2021. It will apply to all pre-packaged non-alcoholic beverages sold in Singapore. It will have four color-coded grades wherein Grade A, corresponding to the lowest sugar and saturated fat thresholds, will be in green and Grade D, corresponding to the highest sugar and saturated fat thresholds, will be in red.
Study NCT06543680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dental restoration
Description: Each patient will randomly receive one cervical restoration with one of the tested restorative systems
Study NCT06543680 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dental restoration
Description: Each patient will randomly receive one cervical restoration with one of the tested restorative systems
Study NCT05792527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: One 500 mg tablet twice daily after meals
Study NCT06234215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation
Description: electrical stimulation during function
Study NCT05870761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT05172232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dermalyzer
Description: To evaluate the diagnostic accuracy of the Dermalyzer device to detect melanoma among cutaneos skin lesions by dermoscopy.
Study NCT03542695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03542695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu-64-DOTA-alendronate
Description: Given IV
Study NCT03542695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03542695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06234215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional task training
Description: functional exercise
Study NCT06234215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional task training
Description: functional exercise
Study NCT04878952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garmin Vivofit Activity Tracker
Description: Activity tracker that is worn on the wrist.
Study NCT05823714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN+AZA+Modified BUCY
Description: Venetoclax: 200mg/day\*7days（It should be combined with triazole antifungal drugs).~Azacytidine: 75mg/ m²/day\*7days.
Study NCT03068247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 10 week treatment
Study NCT03068247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 week treatment
Study NCT06064578 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Project SOLVE
Description: Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
Study NCT06064578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project SOLVE
Description: Project SOLVE is a \~30-minute self-guided digital intervention designed to teach children and adolescents how to set goals and solve problems systematically. Specifically, Project SOLVE is based on problem solving, a core component of cognitive behavioral therapy, a gold standard treatment for internalizing disorders. Project SOLVE uses vignettes, interactive activities, and engaging graphics to teach youth a systematic strategy for solving problems. Project SOLVE was previously found to be effective in reducing mental health symptoms among American children (https://link.springer.com/article/10.1007/s12310-023-09598-7).
Study NCT05987787 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy without suture reinforcement
Description: The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access.
Study NCT05987787 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy with suture reinforcement
Description: The procedure begins by dissecting the small branches of the gastroepiploic arch 6 cm from the pylorus. The dissection continues along the great curvature of the stomach, remaining very close to the gastric wall, up to the short gastric vessels which are also dissected. The stomach is then raised to expose its posterior wall and the adhesions are lysed. His angle is fully mobilized and the left diaphragmatic pillar exposed. The gastric tubule is created on the guide of a 40 F Bugie using mechanical suturing machines with charges of different thickness depending on the thickness of the gastric wall. At this point the bougie is removed and the resected stomach is extracted from the abdomen through the mesogastric access. At this point, it is applied running seromuscular stitches at the proximal third of the stapled line using unidirectional 2/0 barbed sutures to invaginate the staple line completely.
Study NCT04394715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Alert
Description: Providers will see an automated electronic alert for each eligible hyperlipidemia patient at high risk for future atherosclerotic CVD events. This alert will appear when the provider enters the order entry screen in the patient's medical record during the patient's first eligible outpatient visit. The alert consists of a pop up that notifies the physician that the patient is at very high risk for ASCVD events, displays the most recent cholesterol values and the patient's current lipid lowering therapy. It also includes a link to full treatment guidelines for hyperlipidemia, which includes a continuing medical education (CME) option to obtain CME credits.
Study NCT05728073 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP
Description: Patients separated to two groups according to having a ERCP history before the operation
Study NCT05335902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound measurement of the optic nerve sheath diameter
Description: ultrasound measurement of the optic nerve sheath diameter
Study NCT05335902 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA test
Description: MoCA test is a short bedside test for measuring cognitive disfunction
Study NCT05356338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot Intervention to reduce SSB consumption in children and families enrolled in WIC
Description: A 6-month intervention based on the use of 5 components: 2 educational videos, provision of a water-promotion toolkit, a mobile phone application (app), a series of 14 computerized interactive voice response (IVR) phone calls to parents and 2 counseling sessions by a WIC nutritionist to compare families' SSB's consumption behaviors
Study NCT05337592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368 formulation 1
Description: BI 1815368 formulation 1
Study NCT05337592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05337592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1815368 formulation 2
Description: BI 1815368 formulation 2
Study NCT06086028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist worn sensor
Description: Biostrap collects biometrics such as the following: (1) sleep pattern/ quality; (2) steps, activity, calories; (3) heart rate/ HRV; (4) respiratory rate. Participants will be randomly assigned to one of two groups.
Study NCT02500784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol A
Description: 20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
Study NCT02500784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formoterol B (placebo)
Description: 2mL, BID inhaler for 12 months
Study NCT06330727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coffee capsule
Description: Take 12 coffee capsules containing 3.6 g instant black coffee powder per day (take 6 coffee capsules twice daily with breakfast and lunch).
Study NCT06330727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch capsule
Description: Take 12 placebo capsules containing 3.6 g corn starch per day (take 6 placebo capsules twice daily with breakfast and lunch).
Study NCT05240521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ARM A
Description: 30 IBS-C patients will receive GA-AT0119 for 28 days, followed by a washout period of 28 days and Placebo for another 28 days
Study NCT05240521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ARM B
Description: 30 IBS-C patients will receive Placebo for 28 days, followed by a washout period of 28 days and GA-AT0119 for another 28 days